Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 8, 2006, Pages 569-573

  Zhang, Peng ^b   Zhang, Yifan ^a   Chen, Xiaoyan ^a   Li, Rongqin ^c   Yin, Jian ^c   Zhong, Dafang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c People's Hospital of Liaoning Province   (China)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive agent; CAS 144701 48 4; MicardisPlus ; Telmisartan, clinical pharmacokinetics, dose related analysis

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; TELMISARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; HALF LIFE TIME; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN;

EID: 33748483854     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296753     Document Type: Article

References (13)

1. McClellan, K. J., Markham, A., Telmisartan. Drugs 56, 1039 (1998)
2. Wienen, W., Hauel, N., van Meel, J. C. A. et al., Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110, 245 (1993)
3. Stangier, J., Su, C. A. P. F., Roth, W., Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res. 28, 149 (2000)
4. Sharpe, M., Jarvis, B., Goa, K. L., Telmisartan: a review of its use in hypertension. Drugs 61, 1501 (2001)
5. WHO Expert Committee, Guidelines for good clinical practice (GCP) for trials on pharmaceutical products, the use of essential drugs. Sixth report of the WHO Export Committee, WHO Technical Report Series, No. 850 (1995)
6. FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2001), Website: http://fda.gov/cder/guidance/index.htm
7. State Committee of Pharmacopoeia. Guidance for evaluation of bioavailability and bioequivalence of pharmaceutical preparations in human. Chinese Pharmacopoeia, Vol. 2, Appendix XIX B (2005)
8. Müller, C., Schäfer, P., Strörtzel, M. et al., Ion suppression effects in liquid chromatography-electrospray ionization transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J. Chromatogr. B Analyt. Technol. Life Sci. 773, 47 (2002)
9. Shen, J., Jiao, Z., Li, Z. D. et al., HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study. Pharmazie. 60, 418 (2005)
10. Xu, M., Song, J., Liang, Y., Rapid determination of telmisartan in pharmaceutical preparations and serum by linear sweep polarography. J. Pharm. Biomed. Anal. 34, 681 (2004)
11. Xu, M., Song, J., Li, N., Rapid determination of telmisartan in pharmaceuticals and serum by the parallel catalytic hydrogen wave method. Anal. Bioanal. Chem. 377, 1184 (2003)
12. 14C]telmisartan in healthy volunteers. J. Clin. Pharmacol. 40, 1312 (2000)
13. Boehringer Ingelheim Pharmaceuticals Inc., Micardis (telmisartan) tablets 40 mg and 80 mg prescribing information. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; June 1999